Organisation paid for research Program year 2024 Source: CMS Open Payments

Ariel Santos

Neither a doctor nor a teaching hospital

Research payments

$6,395,422

94 payments

Through program year 2024, Ariel Santos is reported as receiving $6,395,422 in research payments, across 94 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$6,794	2
2023	Research	$293,857	26
2022	Research	$3,292,100	32
2021	Research	$2,802,671	34

Breakdown

Who paid Research payments · program years 2021–2024

Pfizer Inc. $6,395,422 94 payments

Studies the money was for Research payments · program years 2021–2024

A Phase 23 Randomized Doubleblind Doubledummy Placebo Controlled Study to Evaluate the Safety and Efficacy of 2 Regimens of Orally Administered PF 07321332Ritonavir in Preventing Symptomatic Sarscov2 Infection in Adult Household Contacts of An Individual With Symptomatic Covid19 $3,249,941 20 payments
An Interventional Efficacy and Safety Phase 23 Doubleblind 2Arm Study to Investigate Orally Administered Pf07321332ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Increased Risk of Progressing to Severe Illness $1,258,020 16 payments
An Interventional Efficacy and Safety Phase 23 Doubleblind 2 Arm Study to Investigate Orally Administered PF 07321332Ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Low Risk of Progressing to Severe Illness $1,252,659 16 payments
An Interventional Efficacy and Safety Phase 2 Randomized Doubleblind 2Arm Study to Investigate A Repeat 5Day Course of Nirmatrelvirritonavir Compared to Placeboritonavir in Participants at Least 12 Years of Age With Rebound of Covid19 Symptoms and Rapid Antigen Test Positivity $507,977 20 payments
An Interventional Efficacy and Safety Phase 2 Randomized Doubleblind 3Arm Study to Investigate Nirmatrelvirritonavir in Nonhospitalized Participants at Least 12 Years of Age With Symptomatic Covid19 Who Are Immunocompromised $72,649 17 payments
A Phase 1 Openlabel Study to Evaluate the Pharmacokinetics Safety and Tolerability of Orally Administered Nirmatrelvirritonavir in Pregnant Women With Mildtomoderate Covid19 $54,176 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.